GTCR To Acquire Surmodics - Quick Facts
(RTTNews) - Surmodics (SRDX) has entered into a definitive agreement to be acquired by GTCR, a private equity firm with investment expertise across healthcare and healthcare technology. The affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million.
Surmodics' Board has unanimously approved the transaction and resolved to recommend that stockholders vote in favor of the transaction. Upon completion, Surmodics will be a privately held company and its common stock will no longer be listed on The Nasdaq Stock Exchange.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.